Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cellaviva is Scandinavia's first and largest private stem cell bank, specializing in the collection and preservation of stem cells from umbilical cord blood and tissue. Operating as a subsidiary of NextCell Pharma AB, the company provides families with a long-term storage solution for hematopoietic and mesenchymal stem cells. These cells are stored for potential future use in treating a variety of medical conditions, including blood disorders and immune system diseases. Cellaviva operates under a license from the Swedish Health and Social Care Inspectorate (IVO) and follows strict GMP standards for tissue banking. Their services are designed to empower parents with a biological insurance policy for their children's future health through state-of-the-art cryopreservation technology. The company maintains a strong presence in Sweden and Denmark, serving as a bridge between families and the future of regenerative medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cellaviva.